Kricker A, Armstrong B, Smith C, Bilous M, Camaris C, Mayer A, Psarianos T
NHMRC National Breast Cancer Centre, NSW, Australia.
Br J Cancer. 1999 May;80(3-4):563-8. doi: 10.1038/sj.bjc.6690392.
To measure the quality of pathology reporting of breast cancer and establish a baseline against which future changes can be measured, we audited item completeness in breast cancer reports in Australia in 1995 before the release of specific recommendations from the Australian Cancer Network. Tumour type and size were given in reports of invasive breast cancer for 93% of women, 70% had, in addition, grade and clearance of the margins while only 28% had all recommended information. The most complete items in reports were histological type of breast cancer (99.6% of cases), tumour size (94%, 95% confidence interval (CI) 92-95) and margins of excision (87%, 95% CI 85-89). Histological grade (84%, 95% CI 82-86 of cases) and presence or absence of ductal carcinoma in situ (DCIS) (79%, 95% CI 77-81) were less complete and vessel invasion (61%, 95% CI 58-63) and changes in non-neoplastic breast tissue adjacent to the breast cancer (68%, 95% CI 66-71) the least complete. Less than half the reports of DCIS reported on tumour size (49%, 95% CI 42-57), presence or absence of necrosis (41%, 95% CI 34-49) or nuclear grade (39%, 95% CI 31-46). Around 1500 reports were identified as issued by 147 laboratories and 392 pathologists; 69% of pathologists issued fewer than two reports a month in the audit. We concluded that infrequency of reporting may have contributed to incompleteness of reporting. In addition, we found significant variation across Australian states with some indication that reporting was consistently poor in one state. The audit highlighted areas for improvement for breast cancer reporting in Australia. Research evidence suggests that multifaceted strategies are needed to assist practitioners with implementing more uniform reporting standards.
为评估乳腺癌病理报告的质量,并建立一个可用于衡量未来变化的基线,我们于1995年在澳大利亚癌症网络发布具体建议之前,对澳大利亚乳腺癌报告中的项目完整性进行了审核。浸润性乳腺癌报告中,93%的女性病例给出了肿瘤类型和大小,70%的病例还给出了分级和切缘情况,而仅有28%的病例包含了所有推荐信息。报告中最完整的项目是乳腺癌的组织学类型(99.6%的病例)、肿瘤大小(94%,95%置信区间(CI)92 - 95)和切除切缘(87%,95% CI 85 - 89)。组织学分级(84%,95% CI 82 - 86的病例)和导管原位癌(DCIS)的有无(79%,95% CI 77 - 81)完整性稍差,血管侵犯(61%,95% CI 58 - 63)和乳腺癌旁非肿瘤性乳腺组织的改变(68%,95% CI 66 - 71)完整性最差。DCIS报告中,不到一半报告了肿瘤大小(49%,95% CI 42 - 57)、坏死的有无(41%,95% CI 34 - 49)或核分级(39%,95% CI 31 - 46)。约1500份报告被确定由147个实验室和392名病理学家出具;69%的病理学家在审核期间每月出具的报告少于两份。我们得出结论,报告频率低可能导致了报告的不完整性。此外,我们发现澳大利亚各州存在显著差异,有迹象表明一个州的报告一直很差。此次审核突出了澳大利亚乳腺癌报告中需要改进的方面。研究证据表明,需要多方面的策略来帮助从业者实施更统一的报告标准。